Amgen (AMGN) Posts Solid Q1, All Eyes Now on Repatha CV Outcomes Trial - BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Amgen (AMGN) PT Raised to $186 at Leerink Partners
April 29, 2016 6:58 AM EDTLeerink Partners analyst Geoffrey Porges raised his price target on Amgen (NASDAQ: AMGN) to $186.00 (from $179.00) following solid Q1 results but stopped short of upgrading the stock and maintained an Market Perform rating.
Porges commented, "Revenue of $5.527bn handily beat consensus by 5%, although it fell short of our estimate of $5.66bn by 2% (Exhibit 1). The main drivers of the revenue... More
Amgen (AMGN) Tops Q1 EPS by 30c, Raises FY Guidance
April 28, 2016 4:03 PM EDTAmgen (NASDAQ: AMGN) reported Q1 EPS of $2.90, $0.30 better than the analyst estimate of $2.60. Revenue for the quarter came in at $5.53 billion versus the consensus estimate of $5.32 billion.
GUIDANCE:
Amgen sees FY2016 EPS of $10.85-$11.20, versus prior guidance of $10.60-$11.00 and... More
